Inflammatory bowel disease clinical service recovery during the COVID-19 pandemic.
No Thumbnail Available
Authors
Steed, Helen
Issue Date
2022-01-01
Journal
Type
Article
Peer-Reviewed Publication
Peer-Reviewed Publication
Keywords
COVID-19
Clinical decision making
Inflammatory bowel disease
Clinical decision making
Inflammatory bowel disease
Journal Title
Frontline Gastroenterology
Volume
13
Issue
1
Begin page
77
End page
81
Abstract
The risk of patients with IBD acquiring SARS-CoV-2 and developing COVID-19 will depend on their inherent personal risk factors and modifiable factors such as active IBD and immunosuppression. Fortunately, we will be able to refine the risk profile for each individual patient iteratively as more data become available.45 46 We recommend that effective treatment for IBD should not be postponed idefinately until patients have received the COVID-19 vaccine Three SARS-CoV-2 vaccines have been approved and the BSG and other organisations are in favour of patients with IBD to accept the first vaccine offered.47 48
Healthcare services and patients have rapidly adjusted to new working practices stimulated by the COVID-19 pandemic. Our next challenge is to truly transform our services using data-driven clinical decision-making, proactively monitoring disease and supporting patient engagement as the pandemic evolves.
Citation
Din S, Gaya D, Kammermeier J, Lamb CA, Macdonald J, Moran G, Parkes G, Pollok R, Sebastian S, Segal J, Selinger C, Smith PJ, Steed H, Arnott ID. Inflammatory bowel disease clinical service recovery during the COVID-19 pandemic. Frontline Gastroenterol. 2021 Apr 21;13(1):77-81. doi: 10.1136/flgastro-2021-101805. PMID: 34966535; PMCID: PMC8666864.